Anti-GPER1/GPR30 (extracellular)-FITC Antibody

GPER1/GPR30 is an estrogen receptor belonging to the superfamily of G-protein coupled receptors (GPCRs). Like all members, GPER1 has seven membrane-spanning domains, an extracellular N-terminus and a cytoplasmic C-terminal domain. It is widely expressed in the central nervous system (CNS) and it binds 17β-estradiol (17β-E) with high affinity¹.

Estrogens have long been known as important regulators of the female reproductive functions, however, is now commonly accepted that estrogens and androgens have important functions in both female and male physiology and pathology.

As opposed to the epigenetic regulatory role in estrogen signaling carried out by ER-α and ER-β estrogen receptors, signaling from GPER1 is responsible for the rapid non-genomic actions of estrogens that activate various protein-kinase cascades¹. GPER1 signaling improves spatial memory, possibly via release of neurotransmitters. In addition, GPER1 activation contributes to behaviors that denote anxiety, and to social behaviors such as social memory and lordosis behavior in mice. In the male hippocampus, GPER1 activation leads to phosphorylation of the classical estrogen receptor ERα, suggesting that crosstalk with ERα is important in the manifestation of these behaviors, many of which are absent in ERα-null mice². GPER1 activation also has several beneficial effects in the cardiovascular system including vasorelaxation, inhibition of smooth muscle cell proliferation, and protection of the myocardium against ischemia/reperfusion injury, and in the metabolic system including stimulation of insulin release and protection against pancreatic β-cell apoptosis. Thus, GPER1 is emerging as a candidate therapeutic target in both cardiovascular and metabolic diseases³.